Research Study Results Bring Hope for Combating Debilitating Diseases - Research Report on Johnson & Johnson, AbbVie, Lilly, Novartis and GlaxoSmithKline

Wed Jun 12, 2013 8:01am EDT

* Reuters is not responsible for the content in this press release.

Research Study Results Bring Hope for Combating Debilitating Diseases - Research Report on Johnson & Johnson, AbbVie, Lilly, Novartis and GlaxoSmithKline

PR Newswire

NEW YORK, June 12, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), AbbVie Inc. (NYSE: ABBV), Eli Lily & Co. (NYSE: LLY), Novartis AG (NYSE: NVS) and GlaxoSmithKline plc. (NYSE: GSK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On June 6, 2013, Janssen R&D Ireland (Janssen), a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, released primary efficacy and safety results from four Japanese Phase 3 clinical studies demonstrating the use of the investigational NS3/4A protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in patients with genotype 1 hepatitis C, when administered once daily with pegylated interferon and ribavirin. The four studies examined the use of simeprevir in patients who were treatment naïve, as well as patients who were non-responders to prior therapy or relapsed following treatment with pegylated interferon with or without ribavirin. The studies supported the new drug application for simeprevir, which was submitted to Japanese regulatory authorities in February 2013. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/0ba3_JNJ]

--

AbbVie Inc. Research Report

On June 3, 2013, AbbVie Inc. (AbbVie) announced results from a Phase 1 study of ABT-199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the most common leukemia in the United States, and relapsed/refractory non-Hodgkin's lymphoma (NHL). The Phase 1 trial was designed to assess the safety, determine the maximum tolerated dose and recommended Phase 2 dose, and evaluate the pharmacokinetics of ABT-199 in patients with relapsed/refractory CLL and NHL. Gary Gordon, M.D., divisional Vice President of AbbVie's Oncology Clinical Development, said, "The ABT-199 data underscore AbbVie's commitment to the development of treatments for some of the hardest-to-treat cancers like CLL and NHL. Early trials of ABT-199 have shown the compound's potential in these hematological malignancies, which support the continuation of its clinical development program." The Full Research Report on AbbVie Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/2433_ABBV]

--

Eli Lily & Co. Research Report

On June 3, 2013, Eli Lilly & Co. (Lilly) announced results from its PRONOUNCE trial of ALIMTA (pemetrexed for injection) for treatment of nonsquamous, non-small cell lung cancer (NSCLC). The PRONOUNCE trial compared an ALIMTA (pemetrexed), carboplatin doublet regimen to a paclitaxel, carboplatin and bevacizumab triplet regimen. The study did not achieve its primary superiority endpoint of improved progression-free survival without grade four adverse events (G4PFS). No significant difference was observed between the treatment arms for secondary endpoints of progression-free survival (PFS), overall survival, overall response rate and disease control rate. Richard Gaynor, M.D., Vice President of Product Development & Medical Affairs for Lilly Oncology, said "The history of ALIMTA clinical evaluation - from histology to its use in the maintenance therapy paradigm - encourages us to explore new avenues to determine if we can improve patient outcomes. These data give us additional insights that further inform the vast body of ALIMTA clinical data." The Full Research Report on Eli Lily & Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/937b_LLY]

--

Novartis AG Research Report

On June 5, 2013, Novartis announced that it will present new data to show that its Gilenya drug (fingolimod), the first once-daily oral therapy approved to treat people with relapsing multiple sclerosis (RMS) has positively impacted the key measures for multiple sclerosis (MS) - relapse rates, brain volume loss, lesions and disability progression, at the 23rd meeting of the European Neurological Society (ENS) on June 10, 2013. New findings from the TRANSFORMS study showed that a greater proportion of patients were disease free after one year on Gilenya treatment compared to interferon. Dr. Timothy Wright, Global Head Development, Novartis Pharmaceuticals, commented, "These new analyses are very encouraging in that they not only support the role of Gilenya as having an anti-inflammatory effect but also highlight how Gilenya can improve the key measures of this debilitating disease." The Full Research Report on Novartis AG - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/956c_NVS]

--

GlaxoSmithKline plc. Research Report

On June 6, 2013, GlaxoSmithKline plc. (GlaxoSmithKline) confirmed that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to continue to make Avandia (rosiglitazone) available to appropriate patients with the majority of the members voting to either modify or remove the Risk Evaluation and Mitigation Strategy (REMS) program in place. Remaining members voted to continue the REMS or withdraw Avandia from the US market. Dr. James Shannon, GSK's Chief Medical Officer, commented, "We appreciate the committee's thorough examination of the RECORD results and will continue to work with the FDA as it considers the recommendation of the committee. We continue to believe that Avandia is a safe and effective treatment option for type 2 diabetes when used for the appropriate patient and in accordance with labeling." Pending the FDA's decision, Avandia will be available through the REMS program to physicians and appropriate patients as an option to help control blood sugar in patients with type 2 diabetes. The Full Research Report on GlaxoSmithKline plc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/2737_GSK]

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquires, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.